Jeito Capital II

About Jeito Capital II

Jeito Capital II is a ~€1 billion ($1.2B) biopharma venture fund — Europe's largest independent biopharma venture vehicle ever raised. Backs 15–20 clinical-stage companies in obesity, oncology, immunology, neurology, and cardio-metabolic disease with ~€150M average tickets. Fund I generated exits to Merck and Biogen totalling up to $4.8B.

Investment Focus

Location / RegionFrance

Funding StageLate Stage

Industry Focus

Biotech

Therapeutics

Investor Signals Profile

active

Sweet Spot

European clinical-stage biotech CEO with Phase 2/3 asset in high-unmet-need disease area

clinical-stage biopharma

patent-cliff M&A

European biotech

concentrated high-conviction

late-stage drug development

Bullish Signals

€1B+ fund closed above target in worst biotech market in a decadeblog

Up to $4.8B exits from Jeito I in average 24-month holding periodblog

€150M average ticket enables leading clinical rounds previously requiring US investorsblog

LP base includes EIB, pension funds, pharma strategics across three continentsblog

Contrarian Signals

15–20 company concentration means single Phase 3 failure hits TVPI hardblog

Not a diversified biotech index — purely high-conviction late-stage betsblog

Early-stage founders get only indirect benefit; not a seed investorblog

Founder Do's

Pitch at Series B or later with clinical-stage asset (Phase 1b–3)

Focus on obesity, oncology, immunology, neurology or cardio-metabolic disease

Prepare deep diligence on target biology, preclinical package and regulatory strategy

Demonstrate clear M&A optionality with large-cap pharma as exit path

Highlight European governance preference and willingness to stay European through pivotal trials

Founder Don'ts

Do not pitch pre-clinical or early discovery-stage assets

Do not rely on narrative-only pitches without rigorous science backing

Do not expect broad diversification — Jeito takes concentrated, high-conviction positions only

Key GPs & Partners

Dr. Rafaèle Tordjman

Founder & Managing Partner

ex-founderthesis-drivenconviction-driven

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund Size€1B

Saves0

Website

Key People

Jeito Capital

Dr. Rafaèle TordjmanFounder & Managing Partner